Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.42)
# 307
Out of 5,163 analysts
240
Total ratings
44.95%
Success rate
27.77%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNAC Cartesian Therapeutics | Upgrades: Overweight | $16 | $7.39 | +116.51% | 1 | Mar 9, 2026 | |
| QURE uniQure | Upgrades: Neutral | $55 → $9 | $15.53 | -42.05% | 11 | Mar 2, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $153 → $125 | $60.04 | +108.19% | 10 | Feb 17, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Maintains: Overweight | $11 → $19 | $7.36 | +158.15% | 2 | Jan 15, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | $21 → $15 | $14.38 | +0.87% | 8 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $20.58 | +133.24% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $7.65 | +213.73% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $6.66 | +185.29% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $9.98 | +140.48% | 4 | Nov 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $32 → $38 | $25.95 | +46.44% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $63 | $49.91 | +26.23% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $21.34 | +392.03% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $64.49 | +82.97% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $60.36 | +22.60% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $7.31 | +118.88% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $30.50 | -1.64% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $16.40 | +393.90% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.49 | +55.90% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $33.76 | +264.39% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.69 | +2,339.02% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.39 | +1,713.47% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $15.15 | +65.02% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $29.51 | +127.04% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.02 | +322.89% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.44 | +227.87% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.61 | +583.23% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $4.76 | +278.15% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $0.66 | +2,020.25% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.16 | +1,020.69% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.11 | +1,791.89% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.61 | +272.67% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.39 | +4,976.14% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $7.17 | +220.78% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $0.94 | +95,441.40% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $2.45 | +3,369.39% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.23 | +2,789.25% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.83 | +9,736.07% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $2.48 | +343.55% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.33 | +4,411.28% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $0.80 | +11,186.68% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.63 | +399,900.00% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $6.19 | +49,011.47% | 1 | Jan 9, 2020 |
Cartesian Therapeutics
Mar 9, 2026
Upgrades: Overweight
Price Target: $16
Current: $7.39
Upside: +116.51%
uniQure
Mar 2, 2026
Upgrades: Neutral
Price Target: $55 → $9
Current: $15.53
Upside: -42.05%
Disc Medicine
Feb 17, 2026
Maintains: Overweight
Price Target: $153 → $125
Current: $60.04
Upside: +108.19%
Eupraxia Pharmaceuticals
Jan 15, 2026
Maintains: Overweight
Price Target: $11 → $19
Current: $7.36
Upside: +158.15%
Amicus Therapeutics
Dec 19, 2025
Downgrades: Neutral
Price Target: $21 → $15
Current: $14.38
Upside: +0.87%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $20.58
Upside: +133.24%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $7.65
Upside: +213.73%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $6.66
Upside: +185.29%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $9.98
Upside: +140.48%
Rigel Pharmaceuticals
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $25.95
Upside: +46.44%
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $49.91
Upside: +26.23%
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $21.34
Upside: +392.03%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $64.49
Upside: +82.97%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $60.36
Upside: +22.60%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $7.31
Upside: +118.88%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $30.50
Upside: -1.64%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $16.40
Upside: +393.90%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $4.49
Upside: +55.90%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $33.76
Upside: +264.39%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.69
Upside: +2,339.02%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.39
Upside: +1,713.47%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $15.15
Upside: +65.02%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $29.51
Upside: +127.04%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $4.02
Upside: +322.89%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.44
Upside: +227.87%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.61
Upside: +583.23%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $4.76
Upside: +278.15%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $0.66
Upside: +2,020.25%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.16
Upside: +1,020.69%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.11
Upside: +1,791.89%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.61
Upside: +272.67%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.39
Upside: +4,976.14%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $7.17
Upside: +220.78%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $0.94
Upside: +95,441.40%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.45
Upside: +3,369.39%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.23
Upside: +2,789.25%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.83
Upside: +9,736.07%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $2.48
Upside: +343.55%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.33
Upside: +4,411.28%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $0.80
Upside: +11,186.68%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.63
Upside: +399,900.00%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $6.19
Upside: +49,011.47%